RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively

RedHill Biopharma Ltd. announced that its partner, the University of Oklahoma, has secured $2.9 million in funding from the National Cancer Institute to conduct clinical trials on the efficacy of RedHill's opaganib following CAR T-cell therapy. The funding will support two phases of trials, with Phase 1b enrolling up to 18 patients to assess safety and dosage, and Phase 2 enrolling an additional 21 patients to gather preliminary effectiveness data. This initiative marks a significant step as CAR T cells will be manufactured on the OU campus, potentially reducing costs and time for treatment.